EGFR and malignant colon neoplasm: This issue has been addressed in several preclinical and clinical studies, which indicate that EGFR blockade and BRAF targeting act synergistically to inhibit ERK pathway signaling in BRAFV600E mutant colon cancers [3, 16, 19].